TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04821752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avoidance Education
Description: Reduction of environmental toxins exposure from the diet will be achieved by switching to organic foods. Reduction of residential and occupational exposure to toxins from household cleaning products, cosmetics, personal care products, and other sources will be achieved by switching to safer products or avoidance of the toxic exposure.
Study: NCT04858009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT05437419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276
Description: Patients will receive an oral dose of TCK-276 QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276 Placebo
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276 Placebo
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276 Placebo
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCK-276 Placebo
Description: Patients will receive an oral dose of TCK-276 matching placebo QD under fed conditions from Day 1 to Day 7.
Study: NCT06080555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose Injection [Ferinject]
Description: For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.
Study: NCT05826652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single injection subcostal transversus abdominis plane block
Description: Single injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 20 ml between tranvers and rectus abdominis muscle immediately next to the linea semilunaris.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple injection subcostal transversus abdominis plane block
Description: Multiple injection subcostal transversus abdominis plane block will be applied with %2,5 Marcaine 5 ml between transverse and rectus abdominis muscle, 5 ml on the transverse muscle near the semilunaris and two more 5 ml volume lateral to this point near the subcostal margin.
Study: NCT04931446

Intervention type: PROCEDURE
Intervention: Biopsy/surgical tissue and peripheral blood
Description: Retrieve specimens stored in the tissue bank, the main types of samples are RNAlater specimens, liquid nitrogen frozen specimens and peripheral blood specimens
Study: NCT06553014

Intervention type: OTHER
Intervention: Endovascular Plug Embolization
Description: Effectiveness of Endovascular Plug Embolization in Pelvic Congestion Syndrome
Study: NCT06556251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIPPEP App
Description: Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PIPPEP App
Description: Digital platform with psichoeducative content in infographics, animated and testimonial videos about:~* psychotic and comorbid symptoms, substance use, available treatments, healthy lifestyle habits, social and health emergency resources and outpatient clinics for young people.~* Regular self-completed questionnaires to measure alarm symptoms, side effects of pharmacological treatment, emotional state, and treatment adherence. There will be a feedback for patients in the form of graphs of the evolution of the different types of questionnaires.~* A bidirectional messaging service with the professional reference team, allowing better accessibility in non-urgent cases.~* A gamification system to encourage use of the application, which includes points, rewards, a leaderboard and mini-games.~* A folder where patients can keep documents they find useful (personal reports, relapse prevention plan, crisis plan).
Study: NCT06350045

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PCNL
Description: percutaneous nephrolithotomy

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PCNL
Description: percutaneous nephrolithotomy
Study: NCT06400446

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The babies in this group will receive the standard care of the unit. The vital signs and pain scores of the babies will be recorded before the mother's visit for seven days. The vital signs and pain scores of the infants who received the standard care of the unit during one hour, which is the time of the mother's visit, will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: Kangaroo care will be applied to the experimental group for seven days. Kangaroo care will be started for the babies in the intervention group when the baby is extubated, when the baby starts oral feeding and when the chest incision is closed. Consistent with previous research, mothers will provide skin-to-skin contact for at least 1 hour per day for seven days, starting immediately after feeding. The vital signs and pain scores of the babies will be recorded during the kangaroo care of the mother for seven days. During the kangaroo care, vital signs and pain scores of the infants will be recorded every 15 minutes for a total of 4 times. The vital signs and pain scores of the infant will be recorded in the first 15 minutes after the mother's visit.
Study: NCT06199440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group III
Description: Third group are Type 2 DM patients who received doxycycline 20mg twice/day.~Gingival crevicular fluid will be collected at 0, 1, and 3 months to assess Serum Resistin using a human Resistin enzyme-linked immunosorbent assay Kit following the manufacturer's protocol.
Study: NCT06153966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION717
Description: ION717 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION717
Description: ION717 will be administered by IT injection.
Study: NCT05414708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: During the art research intervention session, the art therapist will walk you through the creation of various types of art and may spend time asking you about the artwork, how you are felling, as well as your past experiences.
Study: NCT04705324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative Hysteroscopy
Description: Separation of the non-viable gestational sac from the uterine wall will through operative hysteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D&C
Description: Separation of the non-viable gestational sac from the uterine wall through dilation and curettage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative Hysteroscopy - safety and feasibility
Description: Operative hysteroscopy - safety and feasibility phase
Study: NCT03341897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovasculer embolization of varicocele
Description: Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting \< 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise.
Study: NCT05909215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5 microgram/kg
Description: Dexmedetomidine 0.5 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.75 microgram/kg
Description: Dexmedetomidine 0.75 microgram/kg diluted in 20mL of normal saline will be given intravenously through a syringe pump over 10 minutes
Study: NCT04017533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GMK Sphere TKR
Description: Se earlier
Study: NCT06198049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Training
Description: This group will receive Pilates training General rehabilitation exercises. Balance and strengthening exercises. Stretching exercises will be performed.Each exercises will be performed with ten repetition for three sessions per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Proprioception Exercises
Description: This group will receive balance Proprioception exercises. The training program will consist of 14 basic exercises on and off the balance board, with variations on each exercise. Mat walking time per session increased from 6 to 12 min during the acclimation period of the first two sessions and progressed gradually but incrementally to a maximum of 20 min per session over the 12 ensuing sessions.
Study: NCT05417893

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)
Description: The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MeRes 100 Sirolimus-eluting Bioresorbable Vascular Scaffold System (BRS)
Description: The MeRes100™ BRS (Meril Life Sciences Pvt. Ltd., India) is a novel thin-strut second-generation sirolimus-eluting poly-L-lactic acid (PLLA)-based bioresorbable coronary scaffold. The first-in-human MeRes-1 trial demonstrated the safety and effectiveness of MeRes100 BRS in the treatment of de novo coronary lesions with lower major adverse cardiac events (MACE) rate (0.93%) and notably, the absence of scaffold thrombosis at one-year follow-up. MeRes100 sirolimus-eluting bioresorbable vascular scaffold system is expected to bioresorb in the artery, approximately over a period of three years and thus, preventing chance of late clinical events like late scaffold thrombosis rates. The imaging analysis has shown that in-segment late lumen loss and in-scaffold late lumen loss (LLL) did not change significantly at two years follow-up as compared to six months data.
Study: NCT04827654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weekly produce box and gift card
Description: Weekly box of produce (5-10 lbs) and $10.00 gift card to a local grocery store to purchase preferred produce. If progress on self-goals completed, an additional $10.00 card provided, weekly, for 3 weeks.
Study: NCT04935788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk protein
Description: milk protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: micellar casein
Description: micellar casein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pea protein
Description: pea protein supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk/pea protein blend
Description: milk/pea protein supplement
Study: NCT06176625

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Signage
Description: Signage regarding effective communication strategies posted on door to patient's room.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Signage
Description: Signage regarding effective communication strategies posted on door to patient's room.
Study: NCT06153966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching ION717 will be administered by IT injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching ION717 will be administered by IT injection.
Study: NCT06454461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: Upadacinib 15mg once daily for the 8 weeks after NECS
Study: NCT05044845

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Semi structured interview will be conducted virtually using an online video-conferencing platform, phone or in person.
Study: NCT05087602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab and Anlotinib
Description: Toripalimab 240 mg IV on Day 1 of each 14-day cycle plus Anlotinib capsules given 10mg orally in fasting conditions , once daily in 21-day cycles (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).
Study: NCT05948657

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA-PET CT
Description: Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.
Study: NCT04671914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid 20 MG/ML Injectable Solution
Description: Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilation and curretage
Description: After abortion in II trimester we do D\&C.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dilation and curretage
Description: After abortion in II trimester we do D\&C.
Study: NCT05039580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.
Study: NCT05347199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amisulpride Pill
Description: Two single low doses amisulpride (100 mg); orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride Pill
Description: Two single low doses amisulpride (100 mg); orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two doses, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: two doses, orally
Study: NCT06185218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Botulinum Toxin
Description: Botulinum Toxin injections will be made into the bladder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Botulinum Toxin
Description: Botulinum Toxin injections will be made into the bladder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical Botulinum Toxin
Description: Botulinum Toxin injections will be made into the bladder.
Study: NCT05581654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Salpingectomy
Description: Salpingectomy by vaginal natural orifice transluminal endoscopic surgery (v-NOTES).
Study: NCT01927835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA-HIV-PT123 vaccine
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: ≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: ≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM
Study: NCT05347069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No aspirin
Description: No aspirin administered
Study: NCT01927835

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: ≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: ≥ 5x10\^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10\^8 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: ≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: ≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: ≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: ≥ 5x10\^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10\^7 PFU/ml; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E vaccine
Description: 300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA/NYVAC/AIDSVAX
Description: Sodium Chloride for injection, 0.9%; administered IM